Inst. de Oncologia Angel H. Roffo

Buenos Aires C1417DTB

1 studies enrolling now · 1 studies all time

What they study most

Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer

Studies at this site

• A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer) — Recruiting now